Drug-Eluting Stenting Followed by Cilostazol tREAtment Reduces SErious Adverse Cardiac Events (DECREASE-PCI)
Status:
Terminated
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
The DECREASE-PCI trial is a prospective, randomized, placebo controlled, double-blind, phase
4 study to evaluate efficacy and safety of triple anti-platelet therapy compared with dual
antiplatelet therapy in patients treated with DES for Coronary Artery Disease.
The primary objective of this study is to compare the safety and efficacy of triple
antiplatelet therapy versus dual (standard) antiplatelet therapy in patients treated with
drug-eluting stent (DES) implantation for the treatment of coronary artery disease.
Phase:
Phase 4
Details
Lead Sponsor:
Seung-Jung Park
Collaborator:
Otsuka Pharmaceutical Development & Commercialization, Inc.